VBP 926

Drug Profile

VBP 926

Alternative Names: VBP-926

Latest Information Update: 07 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Veloce BioPharma
  • Class Skin disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Skin disorders

Most Recent Events

  • 01 Oct 2017 Phase-II clinical trials in Skin disorders in USA (Topical) (NCT03207906)
  • 28 Jun 2017 Veloce Biopharma plans a phase II trial for Chemotherapy-Associated Paronychia in cancer patients in USA (NCT03207906)
  • 28 Jun 2017 Preclinical trials in Skin disorders in USA (Topical) before June 2017 (NCT03207906)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top